Compare GAB & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GAB | IMCR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | 2016 |
| Metric | GAB | IMCR |
|---|---|---|
| Price | $5.21 | $32.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $62.73 |
| AVG Volume (30 Days) | ★ 1.1M | 503.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 10.91% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $13.06 |
| Revenue Next Year | N/A | $8.12 |
| P/E Ratio | ★ N/A | $139.20 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $5.12 | $27.50 |
| 52 Week High | $6.37 | $40.71 |
| Indicator | GAB | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 57.89 |
| Support Level | $5.12 | $32.03 |
| Resistance Level | $5.72 | $33.62 |
| Average True Range (ATR) | 0.07 | 1.24 |
| MACD | 0.02 | 0.53 |
| Stochastic Oscillator | 52.26 | 76.67 |
Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.